Evidence map›Paper›PMID 36768545›Full record

ArticleInternational journal of molecular sciences2023

Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

Rei Ishihara, Tsukasa Oda, Yuki Murakami, Ikuko Matsumura, Saki Watanabe, Yuta Asao, Yuta Masuda, Nanami Gotoh, Tetsuhiro Kasamatsu, Hisashi Takei and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.International journal of molecular sciences · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rei IshiharaDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.
Tsukasa OdaLaboratory of Mucosal Ecosystem Design, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi 371-8510, Japan.ORCID 0000-0002-8941-161X
Yuki MurakamiDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.
Ikuko MatsumuraDepartment of Haematology, Graduate School of Medicine, Gunma University, Maebashi 371-8510, Japan.
Saki WatanabeDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.
Yuta AsaoDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.
Yuta MasudaDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.ORCID 0000-0002-6923-6199
Nanami GotohDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.
Tetsuhiro KasamatsuDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.ORCID 0000-0002-7943-9176
Hisashi TakeiDepartment of Haematology, Graduate School of Medicine, Gunma University, Maebashi 371-8510, Japan.
Nobuhiko KobayashiDepartment of Haematology, Graduate School of Medicine, Gunma University, Maebashi 371-8510, Japan.
Nobuo SasakiLaboratory of Mucosal Ecosystem Design, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi 371-8510, Japan.ORCID 0000-0002-8798-7244
Takayuki SaitohDepartment of Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Maebashi 371-8510, Japan.
Hirokazu MurakamiFaculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi 371-0823, Japan.
Hiroshi HandaDepartment of Haematology, Graduate School of Medicine, Gunma University, Maebashi 371-8510, Japan.ORCID 0000-0003-3753-9862

Funding

Celgene corporation Non-clinical Research Grant
6 · The paper itself

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) are endogenous matrix metalloproteinase inhibitors. TIMP1 is produced by cancer cells and has pleiotropic activities. However, its role and source in multiple myeloma (MM) are unclear. Here, we evaluated TIMP1 protein and mRNA levels in bone marrow (BM) plasma cells and assessed the effects of TIMP1 expression on fibroblast invasive capacity using three-dimensional spheroid cell invasion assays.

Indexed as

Multiple MyelomaDisease ProgressionFibroblastsHumansPhenotypeRNA, MessengerTissue Inhibitor of Metalloproteinase-1RNA, MessengerTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1fibroblastmultiple myelomatissue inhibitor of metalloproteinasetumour microenvironment

Identifiers

PMID36768545
PMCPMC9917104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.